Provider Statement
This activity is provided by Integrity CE, LLC.
Disclosure of Commercial Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Credits Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This educational program is designed for dermatologists and other physicians as well as nurse practitioners and physician assistants who may be involved in recognizing and managing rare dermatologic conditions such as Generalized Pustular Psoriasis (GPP).
Program Overview
Frequently misdiagnosed or mistaken as infection, is a rare autoimmune disorder that causes systemic as well as cutaneous damage. Marked by recurrent flares, when this chronic disease becomes acute, GPP is characterized by sudden, widespread eruption of painful, pus-filled blisters. Complications can be fatal, and flares necessitate emergency care and immediate treatment. In between flares, patients with GPP live with constant fatigue, pain, and fear of triggers that may bring about another flare. With the recent FDA approval of spesolimab — the first interleukin (IL)-36 receptor antagonist — patients with GPP and their providers have an effective therapy that is indicated for both treating and preventing flares.
Join GPP experts Boni Elewski, MD and Erin E. Boh, MD, PhD, FAAD for their insights on understanding, recognizing and diagnosing, and managing this life-threatening immuno-inflammatory disorder.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Implement patient-centric strategies focused on timely diagnosis of GPP and improved patient-clinician communication about the disease and its treatment
- Explain the pathogenesis of GPP and the rationale for treating it with targeted therapies that inhibit IL-36
- Incorporate information about clinical trial findings for IL-36 inhibitors into selection criteria for treating and preventing GPP flare
Faculty
Boni Elewski, MD - Faculty Chair
Professor and Chair
James E. Elder Endowed Professor for Graduate Education
Department of Dermatology
Heersink School of Medicine
University of Alabama
Birmingham, Alabama
Erin E. Boh, MD, PhD
Joseph Chastain Endowed Chair of Clinical Dermatology
Professor and Chair of Dermatology
Tulane University School of Medicine
New Orleans, Louisiana
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflict of Interest
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:
Boni Elewski, MD
Clinical Research Support: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Incyte, Leo, Novartis, Pfizer, UCB
Consulting Fees: Amgen, Boehringer Ingelheim, Novartis, Ortho Dermatology, Pfizer
Erin E. Boh, MD, PhD
Principal Investigator: AbbVie, Alumis, Bristol Myers Squibb, Boehringer Ingelheim, Castle BioSciences, Corevitas, Dermavant, Janssen, Sanofi
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of December 19, 2025 through December 19, 2026, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].